Gainers
- Minerva Neurosciences NERV stock rose 30.1% to $5.87 during Tuesday's after-market session. Trading volume for this security closed at 1.6 million, accounting for 158.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.3 million.
- NantHealth NH shares increased by 10.54% to $0.47. The market value of their outstanding shares is at $54.1 million.
- Regulus Therapeutics RGLS shares rose 8.6% to $1.64. The market value of their outstanding shares is at $24.0 million.
- Seer SEER stock increased by 7.79% to $10.78. The market value of their outstanding shares is at $674.9 million.
- Talkspace TALK shares increased by 7.0% to $1.68. The company's market cap stands at $265.7 million.
- Endo International ENDP stock moved upwards by 6.3% to $0.33. Trading volume for this security closed at 5.6 million, accounting for 9.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $77.2 million.
Losers
- Reviva Pharmaceuticals RVPH stock fell 7.4% to $1.38 during Tuesday's after-market session. Trading volume for this security closed at 134.4K, accounting for 39.3% of its average full-day volume over the last 100 days. The company's market cap stands at $25.0 million.
- ABVC BioPharma ABVC stock fell 6.82% to $0.82. The market value of their outstanding shares is at $26.7 million.
- Gelesis Holdings GLS stock declined by 6.37% to $1.03. The company's market cap stands at $74.7 million.
- Sharecare SHCR shares declined by 5.62% to $1.68. The market value of their outstanding shares is at $592.0 million.
- Windtree Therapeutics WINT stock fell 5.0% to $0.67. Windtree Therapeutics's trading volume hit 11.5 million shares by close, accounting for 4889.9% of its average volume over the last 100 days. The company's market cap stands at $20.3 million.
- Phio Pharma PHIO shares declined by 4.84% to $0.68. The company's market cap stands at $9.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in